Characterization of the activity of alpha/beta-triglycidylurazol (TGU; NSC-332488): a new antineoplastic compound.
The antitumour properties of alpha/beta-triglycidylurazol (TGU) were investigated on various transplantable mouse tumour systems. A high rate of cures of P388 and L1210 leukaemias was obtained with this compound. TGU also had an antitumour effect against B16 melanoma, the colon 38 tumour and the advanced RC renal carcinoma, producing a total regression of the tumour. Finally, the marked in vivo activity of TGU against a subline of P388 leukaemia totally resistant to cyclophosphamide (CP), its good water-solubility (7%) and its stability in neutral pH are further elements warranting clinical studies with this agent.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D003110:Colonic Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004806:Ependymoma / Q000188:drug therapy; D007680:Kidney Neoplasms / Q000188:drug therapy; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains
D000970:Antineoplastic Agents